MannKind Corporation (MNKD) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

good morning and welcome to the mankind corporation fourth quarter and full year 2025 financial results earnings call as a reminder this call is being recorded on february 26 2026 and will be available for replay on the mankind corporation website shortly after this call and for approximately 90 days This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations. For further information on the company's risk factors, please see the Form 10-K for the annual period ended December 31, 2025, the earnings release, and the slides prepared for this presentation. Joining us today from Mankind are Chief Executive Officer Michael Castagna and Chief Financial Officer Chris Prentice. I'd now like to turn the conference over to Mr. Castagna. Please go ahead, sir. Thanks, operator. Good morning, everyone. Thank you for joining us for our Q4 and year-end 2025 earnings call. Here's today's agenda, and I'll start with some opening remarks. I want to start by taking a step back and putting our relationship with United Therapeutics into context. Tyveso DPI has transformed both United Therapeutics and Mankind's future to fund our respective innovation and growth. Tyveso was a $450 million brand when we entered the collaboration in 2018. And Tyveso DPI quickly grew within 36 months of launch to a billion dollar franchise by delivering a highly impactful therapy that has helped thousands of patients. This success has funded our diversification, setting us up for three important milestones. First, the opportunity to acquire and scale Furosix and invest in inhaled bubetonide dry powder inhalation. Second, it funded our growth of Afrez over the past six years,...